PL3169311T3 - Proszek do stosowania u dzieci do sporządzania zawiesiny doustnej zawierający środek przeciwwirusowy i sposób jego wytwarzania - Google Patents

Proszek do stosowania u dzieci do sporządzania zawiesiny doustnej zawierający środek przeciwwirusowy i sposób jego wytwarzania

Info

Publication number
PL3169311T3
PL3169311T3 PL15730965.9T PL15730965T PL3169311T3 PL 3169311 T3 PL3169311 T3 PL 3169311T3 PL 15730965 T PL15730965 T PL 15730965T PL 3169311 T3 PL3169311 T3 PL 3169311T3
Authority
PL
Poland
Prior art keywords
preparation
suspension containing
antiviral agent
oral suspension
containing antiviral
Prior art date
Application number
PL15730965.9T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthymios Koutris
Vasiliki SAMARA
Ioanna Koutri
Anastasia Kalaskani
Lida Kalantzi
Andreas KAKOURIS
Amalia DIAKIDOU
George GOTZAMANIS
Zaharias GEORGOUSIS
Manolis FOUSTERIS
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of PL3169311T3 publication Critical patent/PL3169311T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15730965.9T 2014-07-17 2015-06-19 Proszek do stosowania u dzieci do sporządzania zawiesiny doustnej zawierający środek przeciwwirusowy i sposób jego wytwarzania PL3169311T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2014001951 2014-07-17
PCT/EP2015/001239 WO2016008560A1 (en) 2014-07-17 2015-06-19 Pediatric powder for oral suspension containing antiviral agent and method for the preparation thereof

Publications (1)

Publication Number Publication Date
PL3169311T3 true PL3169311T3 (pl) 2024-01-15

Family

ID=53483765

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15730965.9T PL3169311T3 (pl) 2014-07-17 2015-06-19 Proszek do stosowania u dzieci do sporządzania zawiesiny doustnej zawierający środek przeciwwirusowy i sposób jego wytwarzania

Country Status (14)

Country Link
US (2) US11969429B2 (pl)
EP (2) EP4134070A1 (pl)
DK (1) DK3169311T3 (pl)
ES (1) ES2960705T3 (pl)
FI (1) FI3169311T3 (pl)
HR (1) HRP20231364T1 (pl)
HU (1) HUE063821T2 (pl)
LT (1) LT3169311T (pl)
PL (1) PL3169311T3 (pl)
PT (1) PT3169311T (pl)
RS (1) RS64688B1 (pl)
SI (1) SI3169311T1 (pl)
SM (1) SMT202300368T1 (pl)
WO (1) WO2016008560A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113060723B (zh) * 2021-03-18 2022-11-04 上海健康医学院 纳米银氨基修饰的还原氧化石墨烯框架材料及其制备方法
WO2026139414A1 (en) 2024-12-24 2026-07-02 Dermax Sa Valacyclovir oral suspensions, their preparation, storage and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ATE536867T1 (de) * 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
EP2197424A2 (en) * 2007-10-17 2010-06-23 Pharmathen S.A. Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
US20090202635A1 (en) * 2008-02-08 2009-08-13 Stephen Michael Scott Delivery System, Application, and Method
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
EP2519264A1 (en) * 2009-12-31 2012-11-07 Ranbaxy Laboratories Limited Taste masked dosage forms of bitter tasting anti-retroviral drugs
US20120149720A1 (en) * 2010-07-30 2012-06-14 Ranbaxy Laboratories Limited Valacyclovir formulations

Also Published As

Publication number Publication date
LT3169311T (lt) 2023-10-25
WO2016008560A1 (en) 2016-01-21
US20170202843A1 (en) 2017-07-20
PT3169311T (pt) 2023-10-11
US20260174767A1 (en) 2026-06-25
DK3169311T3 (da) 2023-10-30
SI3169311T1 (sl) 2023-12-29
RS64688B1 (sr) 2023-11-30
EP4134070A1 (en) 2023-02-15
HRP20231364T1 (hr) 2024-02-16
FI3169311T3 (fi) 2023-11-01
ES2960705T3 (es) 2024-03-06
EP3169311B1 (en) 2023-08-02
EP3169311A1 (en) 2017-05-24
HUE063821T2 (hu) 2024-02-28
US11969429B2 (en) 2024-04-30
SMT202300368T1 (it) 2023-11-13

Similar Documents

Publication Publication Date Title
IL259910A (en) Nicotine particle capsule
ZA201708429B (en) Oral solid formulation containing irinotecan and method of preparing the same
IL258922A (en) Methods for the preparation of obeticholic acid and derivatives thereof
IL252343B (en) Single-dose powder inhaler and method for its production
IL257337A (en) A silica-based biomolecule carrier, a pharmaceutical preparation containing it, a method of preparation and its use
IL256067B (en) System of multiple bags and method for preparing blood components
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
ZA201801015B (en) Oral care compositions and methods of using the compositions
ZA202002088B (en) Acetate powder and method for the preparation thereof
IL262405A (en) Methods for preparing obeticholic acid and its derivatives
IL253174B (en) Nano-particles and methods for their preparation
ZA202002073B (en) Lactate powder and method for the preparation thereof
HUE063821T2 (hu) Gyermekgyógyászati por vírusellenes szert tartalmazó orális szuszpenzióhoz és eljárás elõállítására
IL249463A0 (en) Production method for (s)-2-acetyloxypropionic acid and their derivatives
PT3174521T (pt) Comprimido para mastigar pediátrico contendo agente antiviral e método para a sua preparação
EP3131546A4 (en) Oral rapamycin preparation and use for stomatitis
ZA201801345B (en) Deferasirox-containing powder and method for preparing same
GB201506705D0 (en) Oral suspension
SMT202100362T1 (it) Composizione farmaceutica comprendente darunavir e metodo per la preparazione
SG11201608653YA (en) Preparation method for high-purity 4'-galactosyl-lactose composition